Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has announced a public offering of 32 million shares at a price of $1.30 per share, aiming to raise approximately $41.6 million before expenses [1] Group 1: Public Offering Details - The public offering consists of 32,000,000 shares priced at $1.30 each, with expected gross proceeds of $41.6 million [1] - The offering is set to close on or about February 2, 2026, pending customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 4,800,000 shares at the public offering price [1] Group 2: Concurrent Private Placement - Lexicon will also conduct a concurrent private placement, selling 22,400,000 shares of common stock and 184,366 shares of Series B Convertible Preferred Stock for expected gross proceeds of approximately $41.1 million [2] - The Series B Convertible Preferred Stock will convert into 9,218,290 shares of common stock, with an additional option for the purchaser to buy more shares [2] - The private placement is also scheduled to close on or about February 2, 2026, and is not contingent on the public offering [3] Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be used to fund ongoing research and development of drug candidates, as well as for working capital and general corporate purposes [4] Group 4: Regulatory Information - A shelf registration statement for the public offering was filed with the SEC and declared effective [5] - The securities offered in the private placement will not be registered under the Securities Act [3]